HRP20140375T1 - Postupak za proizvodnju virusnih cjepiva - Google Patents

Postupak za proizvodnju virusnih cjepiva Download PDF

Info

Publication number
HRP20140375T1
HRP20140375T1 HRP20140375AT HRP20140375T HRP20140375T1 HR P20140375 T1 HRP20140375 T1 HR P20140375T1 HR P20140375A T HRP20140375A T HR P20140375AT HR P20140375 T HRP20140375 T HR P20140375T HR P20140375 T1 HRP20140375 T1 HR P20140375T1
Authority
HR
Croatia
Prior art keywords
virus
cells
liquid
viral antigens
deactivation
Prior art date
Application number
HRP20140375AT
Other languages
English (en)
Croatian (hr)
Inventor
Otfried Kistner
Christa Tauer
Noel Barrett
Wolfgang Mundt
Original Assignee
Baxter International Inc.
Baxter Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Baxter Healthcare S.A. filed Critical Baxter International Inc.
Publication of HRP20140375T1 publication Critical patent/HRP20140375T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20140375AT 2007-08-28 2008-08-28 Postupak za proizvodnju virusnih cjepiva HRP20140375T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96672407P 2007-08-28 2007-08-28
PCT/US2008/074559 WO2009029695A1 (en) 2007-08-28 2008-08-28 Method for producing viral vaccines

Publications (1)

Publication Number Publication Date
HRP20140375T1 true HRP20140375T1 (hr) 2014-06-20

Family

ID=39947984

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140375AT HRP20140375T1 (hr) 2007-08-28 2008-08-28 Postupak za proizvodnju virusnih cjepiva

Country Status (16)

Country Link
US (2) US8497112B2 (https=)
EP (1) EP2192917B1 (https=)
JP (1) JP5535910B2 (https=)
KR (1) KR101760844B1 (https=)
CN (1) CN101790381B (https=)
AU (1) AU2008293513B2 (https=)
BR (1) BRPI0816130A2 (https=)
CA (1) CA2696090C (https=)
ES (1) ES2459166T3 (https=)
HR (1) HRP20140375T1 (https=)
IL (1) IL203869A (https=)
PL (1) PL2192917T3 (https=)
RU (1) RU2496519C2 (https=)
SG (1) SG10201404101RA (https=)
SI (1) SI2192917T1 (https=)
WO (1) WO2009029695A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US20130039943A1 (en) * 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2841604C (en) * 2011-07-20 2020-01-21 Abbott Biologicals B.V. Process for producing viral antigen and vaccines
ES2726975T3 (es) * 2011-07-27 2019-10-11 Flash Therapeutics Método para la producción de partículas retrovíricas útiles para transducir células eucariotas
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2015059065A1 (en) * 2013-10-22 2015-04-30 Roche Diagnostics Gmbh Methods for measuring cell-free virus particles from dried blood spots
FR3025107B1 (fr) * 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN111979120B (zh) * 2019-05-23 2022-09-27 比欧联科供应链管理(北京)有限公司 一种狂犬疫苗核酸消化去除装置及实验方法
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (https=) * 1974-01-14 1977-07-15 Sandoz Ag
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2533548B1 (fr) * 1982-09-28 1985-07-26 Degremont Procede et appareil de traitement anaerobie d'eaux residuaires dans un filtre a remplissage de materiau granulaire
EP0172433A3 (en) * 1984-08-02 1989-04-05 Tektronix, Inc. Display method and apparatus employing cursor panning
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
RU2082433C1 (ru) * 1992-07-13 1997-06-27 Николай Владимирович Костючек Способ вакцинопрофилактики гриппа
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6841374B1 (en) * 1998-10-05 2005-01-11 Research Foundation For Microbial Diseases Of Osaka University Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
CA2355270A1 (en) 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
KR20030046395A (ko) 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
RU2195959C1 (ru) * 2001-11-02 2003-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Инактивированная вакцина против синдрома гидроперикардита кур
RU2261111C1 (ru) * 2004-04-08 2005-09-27 Сергеев Виталий Александрович Инактивированная вакцина против вирусных пневмогастроэнтеритов крупного рогатого скота и телят и способ профилактики вирусных пневмогастроэнтеритов
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine

Also Published As

Publication number Publication date
ES2459166T3 (es) 2014-05-08
CA2696090A1 (en) 2009-03-05
RU2496519C2 (ru) 2013-10-27
BRPI0816130A2 (pt) 2015-02-24
KR20100075865A (ko) 2010-07-05
US8497112B2 (en) 2013-07-30
KR101760844B1 (ko) 2017-07-24
CN101790381B (zh) 2014-08-27
SI2192917T1 (sl) 2014-05-30
WO2009029695A1 (en) 2009-03-05
AU2008293513A1 (en) 2009-03-05
JP2010537641A (ja) 2010-12-09
EP2192917B1 (en) 2014-01-29
HK1143328A1 (en) 2010-12-31
SG10201404101RA (en) 2014-09-26
IL203869A (en) 2016-05-31
RU2010111747A (ru) 2011-10-10
PL2192917T3 (pl) 2014-06-30
AU2008293513B2 (en) 2013-11-21
CN101790381A (zh) 2010-07-28
CA2696090C (en) 2017-06-13
US20130287811A1 (en) 2013-10-31
US20090060950A1 (en) 2009-03-05
EP2192917A1 (en) 2010-06-09
JP5535910B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
HRP20140375T1 (hr) Postupak za proizvodnju virusnih cjepiva
JP2010537641A5 (https=)
US11629339B2 (en) Aseptic purification process for viruses
RU2014101484A (ru) Способ получения вирусного антигена и вакцин
JP2009034115A5 (https=)
KR20120033334A (ko) 백신 제조를 위한 고역가 폴리오바이러스의 제조
Trabelsi et al. Purification of rabies virus produced in Vero cells grown in serum free medium
RU2014129788A (ru) Вакцины против hpv
KR20050027164A (ko) 세포 배양물에서 바이러스의 증식 방법
CN106574252A (zh) 从细胞培养物中纯化脊髓灰质炎病毒的方法
Patel et al. Molecular and immunogenic characterization of BHK-21 cell line adapted CVS-11 strain of rabies virus and future prospect in vaccination strategy
JP2016529908A5 (https=)
CN105349499A (zh) 一种禽流感全病毒颗粒标记疫苗的制备方法及其产品和用途
WO2012171329A1 (zh) 一种核酸分离的方法及其应用
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
CN105543179A (zh) 一种高滴度基因i型猪乙型脑炎病毒毒株及其用途
CN102614508A (zh) 一种人用流感病毒裂解疫苗的病毒裂解灭活方法
KR101581228B1 (ko) 바이러스의 증식을 위한 ２-단계 온도 프로파일
Liang et al. Research of Recombinant Influenza A Virus as a Vector for Mycoplasma Pneumoniae P1a and P30a
CN110669739A (zh) 一种新型甲型肝炎病毒抗原制备方法
CN111527202B (zh) So3色谱在病毒纯化方法中的应用
Prokopenko et al. Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain
Calle Human cell-based in vitro systems for vaccine evaluation
CN106434570A (zh) 一种狂犬病病毒裂解液及其应用
EP2606128A1 (de) Permanente humane amniozyten zelllinie zur herstellung von influenzaviren